Drug Price Competition Act of 1983
Amendments propose changes to this bill. Members vote on amendments separately before the final bill vote. An agreed amendment becomes part of the bill; a failed amendment does not.
5 failed 5 pending / other
| Amendment | Sponsor | Status |
|---|---|---|
| HAMDT 1,097 | — | Pending |
| HAMDT 1,094 | — | Failed |
| HAMDT 1,093 | — | Failed |
| HAMDT 1,092 | — | Failed |
| HAMDT 1,091 | — | Pending |
| HAMDT 1,090 | — | Pending |
| HAMDT 1,089 | — | Pending |
| HAMDT 1,088 | — | Failed |
| HAMDT 1,087 | — | Failed |
| HAMDT 1,086 | — | Pending |
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Drug Price Competition Act of 1983 - Amends the Federal Food, Drug, and Cosmetic Act to exempt from Food and Drug Administration (FDA) clinical application requirements new drugs that are the same as previously approved new drugs (extends FDA abbreviated drug application procedures to post-1962 new generic drugs).
House Incorporated this Measure (Amended) in S.1538 as an Amendment.
Cite this page
U.S. Congress. (2026). H.R. 3605: Drug Price Competition and Patent Term Restoration Act of 1984. 98th Congress. Open America. https://openamerica.io/bill/98-HR-3605/
"H.R. 3605: Drug Price Competition and Patent Term Restoration Act of 1984." 98th Congress, 2026, Open America, https://openamerica.io/bill/98-HR-3605/.
H.R. 3605, 98th Cong. (2026), https://openamerica.io/bill/98-HR-3605/.
[H.R. 3605: Drug Price Competition and Patent Term Restoration Act of 1984](https://openamerica.io/bill/98-HR-3605/)